Article
Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
The Prostate - 15 Feb 2010
Terada Naoki, Shimizu Yosuke, Yoshida Toru, Maeno Atsushi, Kamba Tomomi, Inoue Takahiro, Nakamura Eijiro, Kamoto Toshiyuki, Ogawa Osamu
Abstract excerpt
BACKGROUND: The mechanisms underlying antiandrogen withdrawal syndrome (AWS) and alternative antiandrogen therapy (AAT) effectiveness were assumed to be mutations in the androgen receptor (AR), which resulted in an altered response to antiandrogens. The aim of the present study was to test this assumption using the novel prostate cancer xenograft model KUCaP-1 harboring the W741C mutant AR (Yoshida et al., Cancer...
Topics
- Administration, Oral
- Androgen Antagonists
- Androgens
- Anilides
- Animals
- Antineoplastic Agents, Hormonal
- Cysteine
- Drug Administration Schedule
- Flutamide
- Humans